

## **Ventripoint Diagnostics Exhibiting at the 2022 British Society of Echocardiography**

**Toronto, Ontario – The Newswire – October 14, 2022** - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it will be hosting an exhibit at the 2022 British Society of Echocardiography Conference in London, England from October 14-15, 2022.

Dr. Gregory Skinner, one of Ventripoint's clinical advisors will be giving a presentation on his experience using the VMS system. This will provide excellent exposure for the VMS system and its capabilities for cardiologists and clinicians. This conference will further connect Ventripoint to the global echo community and demonstrate how the VMS+ is a reliable and effective cardiac diagnostic tool. Ventripoint's local UK distributor, Cardiologic, will also be participating in the event. This will also provide valuable networking opportunities for Ventripoint's global partners. This will be the tenth conference the Company has exhibited at this year as it continues to the process of introducing a new diagnostic device to the cardiology community.

The British Society of Echocardiography (BSE) is a registered charity that supports clinical echocardiography professionals in order to provide the highest standard of care in echocardiography. BSE was formed in 1990 and has over 4,000 members worldwide. The conference is the BSE's 30<sup>th</sup> annual conference and has the highest attendance to date. The conference will be attended both in person and virtually, offering a unique hybrid experience.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams  
[gadams@venripoint.com](mailto:gadams@venripoint.com)  
519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

## **Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.